Hpv

Understanding the risks of HPV and the importance of its prevention is crucial for protecting against HPV-related cancers, such as cervical, throat, and anal cancers.

Serum Institute of India aims to significantly boost supply of its human papillomavirus (HPV) vaccine as it gears up to provide its shots to the government at cheaper rates for an immunisation campaign this year against the cancer-causing virus.

Immunization is essential for preventing cancer, especially when it comes to Hepatitis B and the Human papillomavirus (HPV).

The Centre on Saturday said it is yet to take a decision on the roll-out of human papillomavirus (HPV) vaccination against cervical cancer in the country.

The indigenously developed quadrivalent HPV vaccine may be considered for introduction in the Universal Immunisation programme (UIP) as a two-dose regimen for adolescent girls aged 9-14 years, Rajya Sabha was informed today.

The Serum Institute's made-in-India vaccine against cervical cancer, CERVAVAC, will be available in the market this month at an MRP of Rs 2,000 per vial of two doses, official sources said on Thursday.

In certain cases, HPV doesn't always cause symptoms, and here the only way to be sure of the cervical cancer status is through regular screening.

India would be in a position to roll out the indigenously developed Human Papillomavirus Vaccine (HPV) against cervical cancer for girls in the age group of 9-14 under the National Immunisation Programme by mid-2023, NTAGI chairperson Dr NK Arora sai

The Human Papillomavirus (HPV) CERVAVAC vaccine, for the prevention of cervical cancer, is expected to arrive in India by April at the one-tenth of the cost of internationally branded vaccines in the country.

Serum Institute of India (SII) had to defer HPV vaccine production by two years due to the focus on Covid, and will start supplying small quantities of the dose to the Indian government in early 2023, a top official has said.

India's first indigenously developed quadrivalent Human Papilloma Virus (HPV) vaccine for the prevention of cervical cancer will be launched in a few months and made available to the people in theaffordable price range of Rs 200-400.

Cervical cancer is a type of cancer which usually occurs in the cells of the cervix, the lower part of the uterus connecting the vagina. Predominantly, cervical cancer is a result of contracting the human papillomavirus (HPV) infection.

World Cancer Day 2021: The most common cause of cervical cancer is human papillomavirus infection. An HPV infection can infect cells on the surface of the skin and the lining of the genitals. Read below to know more.

World Cancer Day: Cervical cancer is one of the most common kinds of cancer amongst Indian women after breast cancer, accounting for 22.86% of all cancer cases. Dr Shishir Shetty talks about the importance of timely screening and diagnosis of cervical cancer.

Cervical cancer: "Awareness about cervical cancer is extremely poor among common people; that makes containing the disease a challenge," Anjila Aneja, Director at Fortis La Femme, New Delhi, told IANS.

Understanding the risks of HPV and the importance of its prevention is crucial for protecting against HPV-related cancers, such as cervical, throat, and anal cancers.

Serum Institute of India aims to significantly boost supply of its human papillomavirus (HPV) vaccine as it gears up to provide its shots to the government at cheaper rates for an immunisation campaign this year against the cancer-causing virus.

Immunization is essential for preventing cancer, especially when it comes to Hepatitis B and the Human papillomavirus (HPV).

The Centre on Saturday said it is yet to take a decision on the roll-out of human papillomavirus (HPV) vaccination against cervical cancer in the country.

The indigenously developed quadrivalent HPV vaccine may be considered for introduction in the Universal Immunisation programme (UIP) as a two-dose regimen for adolescent girls aged 9-14 years, Rajya Sabha was informed today.

The Serum Institute's made-in-India vaccine against cervical cancer, CERVAVAC, will be available in the market this month at an MRP of Rs 2,000 per vial of two doses, official sources said on Thursday.

In certain cases, HPV doesn't always cause symptoms, and here the only way to be sure of the cervical cancer status is through regular screening.

India would be in a position to roll out the indigenously developed Human Papillomavirus Vaccine (HPV) against cervical cancer for girls in the age group of 9-14 under the National Immunisation Programme by mid-2023, NTAGI chairperson Dr NK Arora sai

The Human Papillomavirus (HPV) CERVAVAC vaccine, for the prevention of cervical cancer, is expected to arrive in India by April at the one-tenth of the cost of internationally branded vaccines in the country.

Serum Institute of India (SII) had to defer HPV vaccine production by two years due to the focus on Covid, and will start supplying small quantities of the dose to the Indian government in early 2023, a top official has said.

India's first indigenously developed quadrivalent Human Papilloma Virus (HPV) vaccine for the prevention of cervical cancer will be launched in a few months and made available to the people in theaffordable price range of Rs 200-400.

Cervical cancer is a type of cancer which usually occurs in the cells of the cervix, the lower part of the uterus connecting the vagina. Predominantly, cervical cancer is a result of contracting the human papillomavirus (HPV) infection.

World Cancer Day 2021: The most common cause of cervical cancer is human papillomavirus infection. An HPV infection can infect cells on the surface of the skin and the lining of the genitals. Read below to know more.

World Cancer Day: Cervical cancer is one of the most common kinds of cancer amongst Indian women after breast cancer, accounting for 22.86% of all cancer cases. Dr Shishir Shetty talks about the importance of timely screening and diagnosis of cervical cancer.

Cervical cancer: "Awareness about cervical cancer is extremely poor among common people; that makes containing the disease a challenge," Anjila Aneja, Director at Fortis La Femme, New Delhi, told IANS.